Christine Frissora, MD: Vibrant vs Linaclotide for Chronic Idiopathic Constipation скачать в хорошем качестве

Christine Frissora, MD: Vibrant vs Linaclotide for Chronic Idiopathic Constipation

A common lower GI tract disorder of gut-brain interaction, chronic idiopathic constipation affects approximately 8%–12% of the US population and can be associated with symptoms such as infrequent and incomplete defecation. While linaclotide currently serves as the standard of care for pharmacologic management of the condition, Christine Frissora, MD, an associate attending physician at New York-Presbyterian Hospital and an associate professor of clinical medicine at Weill Cornell Medical College, explained to HCPLive how the Vibrant System might offer a cost-effective alternative. “We think [Vibrant] could be a very good, effective first-line therapy for chronic idiopathic constipation,” she said. An orally administered drug-free capsule, Vibrant was granted marketing authorization by the US Food and Drug Administration for the treatment of adults with chronic idiopathic constipation in 2023. The drug-free treatment is thought to enhance colonic motility by augmenting the biological clock via mechanical stimulation of the colon. Results of Frissora’s cost-effectiveness analysis suggest the Vibrant System is associated with cost savings in both direct and indirect costs as well as improved quality of life relative to linaclotide. https://www.hcplive.com/view/christin... #Gastro #Gastroenterology #Constipation #Linaclotide